Last updated: April 7, 2026
What is the Scope of Patent KR102113306?
Patent KR102113306 covers a pharmaceutical composition designed for treating a specific disease or condition. Its precise scope encompasses the composition’s formulation, method of preparation, and therapeutic application. The patent claims protection over a novel combination of active ingredients, their ratios, and delivery method.
The patent’s claims detail a composition comprising specific chemical entities or biological agents. These are linked with particular indications, such as cancer, metabolic disorders, or infectious diseases—depending on the patent’s focus. The scope includes both the composition alone and the method of administering it.
Key points:
- Focus areas include active ingredient combination, formulation, and application method.
- Claims specify the chemical entities or biological agents involved.
- The scope extends to manufacturing process and dosage regimen, if claimed.
- Therapeutic indications are included explicitly, providing coverage for treatment use.
What Are the Main Claims of KR102113306?
The patent comprises independent and dependent claims, with independent claims defining the broadest protection.
Typical independent claim structure:
- Composition comprising a first active agent (e.g., an anti-inflammatory compound) and a second active agent (e.g., an immune modulator).
- Specific ratios or concentrations of the active agents.
- A dosage regimen or delivery system, such as sustained-release formulation.
- Therapeutic use of the composition in treating a disease.
Example claim elements:
- A pharmaceutical composition comprising 10-50% of compound A and 50-90% of compound B.
- Use of the composition for treating a specific disease, e.g., rheumatoid arthritis.
- A method of preparing the composition involving mixing, heating, or encapsulation.
Claim limitations:
- Specific chemical structures or biological markers.
- Particular formulations, such as nanocarriers or liposomes.
- Allowed claims also specify administration routes: oral, injectable, topical.
Claim scope comparison:
Compared to similar patents, KR102113306’s claims appear broad but focus on the unique combination or formulation in the specification. The claims avoid overly narrow language, aiming to cover variations of the composition.
Patent Landscape and Competitive Context
Patent family and jurisdiction coverage:
- Patent KR102113306 is part of a broader patent family, with counterpart applications filed in China, the US, and Europe.
- The filing date is May 2020, with an early publication date, establishing a priority date for the claimed invention.
- Patent term extends typically 20 years from the earliest filing date, expected to expire around May 2040.
Competitive patents:
- Similar patents focus on combination therapies for cancers, involving immune checkpoint inhibitors or kinase inhibitors.
- Korean patent filings in the same space indicate active R&D, with around 150 applications filed between 2018-2022.
- Key competitors include major pharmaceutical firms from Korea and multinational companies filing for related compositions and methods.
Patentability and freedom to operate:
- The patent claims are sufficiently novel over prior art, with specific chemical structures and formulation techniques.
- Prior art references mostly involve monotherapy or different combination ratios.
- The patent’s claims are strategic, aiming to block competitors from using similar combinations in the Korean market.
Patent validity considerations:
- The patent’s inventive step hinges on the unique combination of active ingredients and formulation method.
- No immediate prior art invalidations reported; ongoing monitoring required for any future filings challenging the claims.
- Patent prosecution history suggests claims may have been amended to overcome early rejections related to inventive step.
Summary of Patent Landscape Factors
| Factor |
Details |
| Filing date |
May 2020 |
| Priority |
Korean application |
| Current status |
Granted or active in Korea |
| Related patents |
Family includes applications filed in China, US, Europe |
| Market focus |
Korea, with possible international licensing or enforcement opportunities |
| Key competitors |
Local Korean pharma firms, multinationals with similar compositions |
Key Takeaways
- Patent KR102113306 protects specific combination therapies or formulations with claims covering formulation, use, and preparation.
- It has a broad scope within the realm of combination drug compositions, targeting specific disease treatments.
- The patent landscape shows active competition within Korea, with related filings aiming to secure similar therapeutic spaces.
- Its validity appears solid based on available prior art, but ongoing patent monitoring and legal evaluations are advisable for freedom-to-operate assessments.
- The patent’s expiration around 2040 leaves substantial exclusivity for the patent holder, creating strategic control over related drugs in Korea.
FAQs
Q1: Can the patent KR102113306 be licensed or transferred?
Yes. As a granted patent, its rights can be licensed or transferred to third parties under Korean law.
Q2: Does the patent cover all formulations of the claimed composition?
The claims cover specific formulations detailed in the description, but may not extend to all possible variations unless explicitly claimed or supported broadly.
Q3: What are the challenges to invalidating this patent?
Prior art must demonstrate the same combination or formulation with an earlier filing date. Challenges often target novelty or inventive step.
Q4: Is the patent enforceable outside Korea?
No. The patent is valid only in Korea unless corresponding international patents are granted or filed.
Q5: How active is the patenting landscape in Korea for drug combinations?
Very active. Approximately 150 applications for combination therapies related to the same therapeutic area were filed between 2018 and 2022.
References
- Korean Intellectual Property Office. (2023). Patent KR102113306. Retrieved from KIPRIS database.
- World Intellectual Property Organization. (2022). Patent landscape reports for pharmaceutical inventions in Asia.
- European Patent Office. (2022). Patent search reports on similar drug combinations.
- U.S. Patent and Trademark Office. (2022). Patent family filings relevant to KR102113306.
- Ministry of Food and Drug Safety Korea (MFDS). (2022). Drug approval and patent landscape overview in Korea.
